NAPA, Calif., Jan. 7 /PRNewswire/ -- Integrated Biosystems, Inc. (IBI), the world's leading supplier of controlled freeze-thaw technology to the biopharmaceutical industry, today announced receipt of the first major order for the new Celsius product line. This follows the recent announcement in December of the largest order book in the company's history. Orders for Celsius, which is just being introduced into the market, now total several million dollars and serve to confirm that the product launch is on schedule and moving according to plan. The Celsius product line offers the company's proprietary freeze-thaw technology in disposable containers.
John H. Brown, President and Chief Executive Officer of Integrated Biosystems, Inc. commented, "Integrated Biosystems has embarked on a major program to develop and commercialize the Celsius range of products and it is very pleasing to see the momentum building so rapidly in its adoption by the market. We expect it to have a substantial impact on the way pharmaceutical companies design and implement manufacturing operations for the new high growth biopharmaceutical products".
Integrated Biosystems is the market leader in controlled freeze-thaw technology for holding, storing and shipping biopharmaceutical materials. The first product line -- stainless steel vessels sold under the CryoFin brand -- was introduced in 1998 and continues to see strong growth. The company is now introducing its Celsius product line, which offers similar technology in disposable, pre-sterilized, flexible containers. There are significant benefits to using disposable containers, which IBI sells under the brand name Celsius-Pak, including the elimination of expensive and time consuming cleaning procedures in the biopharmaceutical manufacturing operation. In addition, Celsius provides many other advantages in the logistics of moving and storing product within the manufacturing facility and between plants located in different parts of the country or overseas. This is because a typical Celsius system consists not only of freeze-thaw modules and control units but also transfer carts, storage modules, shipping containers and protective frames for the Celsius-Paks.
"The company's strategy from the inception of the Celsius development program was to provide a disposable-based solution for improving the efficiency of biopharmaceutical manufacturing operations," said Eric K. Lee, Vice President of Research and Development. "The very positive response that we are experiencing from our customers confirms that the company is on track to achieving the goals we defined for Celsius."
Integrated Biosystems is firmly established as a leading supplier to the biopharmaceutical manufacturing industry, selling equipment to seven of the top eight biopharmaceutical manufacturers which is used in the manufacturing of six of the top eight biopharmaceutical products on the market today.
About Integrated Biosystems, Inc.
Integrated Biosystems, Inc. (IBI) is the world's leading supplier of patented technology and equipment for the controlled freezing, thawing and frozen storage of biopharmaceutical intermediates and final bulk drug substances. IBI's product portfolio includes freeze-thaw systems and related handling equipment for R&D, Pilot and Full-Scale Manufacturing. The technology has been used for over 10 years at leading Biotechnology and Biopharma contract manufacturers and is currently an integral part of the manufacture of a variety of leading biopharmaceuticals.
IBI is a private company headquartered in Napa, CA with European facilities in Fribourg (Switzerland) and Aubagne (France) and Engineering and Manufacturing operations in Springfield, MO.
For further information contact Richard Eagling, Vice-President Marketing and General Manager, Europe (firstname.lastname@example.org) or go to http://www.integratedbio.com/.
Integrated Biosystems, Inc.